Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782210 | 0.93 | OPRL1 (0.78) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3413521 | 0.90 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| Bicarbonate SCHEMBL5156531 | 0.86 | OPRL1 (0.67) | OPRL1OPRM1OPRK1 | |
| Bicarbonate SCHEMBL5162054 | 0.84 | OPRL1 (0.64) | OPRL1OPRM1OPRK1 | |
| SCHEMBL6249783 | 0.82 | OPRL1 (0.75) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13695532 | 0.80 | OPRL1 (0.79) | OPRL1OPRM1OPRK1 | |
| SCHEMBL2834926 | 0.80 | OPRM1 (0.72) | OPRL1OPRM1OPRK1 | |
| SCHEMBL8352749 | 0.79 | OPRL1 (0.58) | OPRL1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL2331328 | 0.79 | OPRL1 (0.69) | OPRL1OPRM1OPRK1 | |
| SCHEMBL22540247 | 0.79 | OPRL1 (0.69) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020120606-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120539-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | disclosed |